INS and fatty liver disease: PPARγ agonist. Primarily acts on adipocytes, promoting adipocyte differentiation and increasing lipid storage capacity, thereby reducing free fatty acid flux to the liver. This action improves insulin sensitivity and effectively alleviates hepatic steatosis. Some studies show it can also inhibit the activation of hepatic stellate cells (HSCs), reducing fibrosis